Business Context and Reporting Period
Company: Biote Corp. (BTMD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Biote operates a practice-building platform in the hormone optimization space, training practitioners in the "Biote Method" (bioidentical hormone pellet therapy) and selling complementary dietary supplements. The company generates revenue through procedure-based fees and product sales to over 8,600 certified practitioners in more than 4,700 clinics.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $197.2 million | $185.4 million |
| Net Income (Loss) | $0.05 million | ($2.8) million |
| Adjusted EBITDA | $58.2 million | $55.3 million |
| Operating Income | $31.6 million | $28.7 million |
| Cash and Cash Equivalents | $39.3 million | $89.0 million |
| Long-Term Debt (Net) | $101.2 million | $106.6 million |
| Share Repurchase Liability | $68.9 million | $0 |
Note: Net income was significantly impacted by non-cash losses related to changes in fair value of earnout liabilities ($19.6 million) and accreted interest on share repurchase liabilities ($2.6 million).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 6.4% to $197.2 million, driven by a 20.3% increase in pellets dispensed and the acquisition of Asteria Health (a 503B compounding facility). This was partially offset by a $2.1 million decline in dietary supplement revenue due to a transition to an Amazon e-commerce platform.
- Profitability: The company returned to net income ($0.05 million) from a net loss of $2.8 million in 2023. However, this was largely due to the absence of a $13.4 million loss from warrant liability changes in 2023 and a reduction in earnout liability fair value losses.
- Acquisitions: Completed the acquisition of Asteria Health for $9.0 million and asset purchases of Simpatra and BioSana to verticalize the supply chain.
- Litigation Settlements: Settled significant litigation with former stockholders (Donovitz and Marci M. Donovitz) and a vendor (Right Value), resulting in a combined share repurchase liability of $128.4 million and a $5.0 million cash settlement liability.
- Leadership Change: Bret Christensen was appointed CEO effective February 1, 2025, replacing Teresa S. Weber.
Guidance, Outlook, and Risks
Outlook and Strategy: Management plans to expand U.S. geographic footprint and field sales staff in 2025. The company is focusing on vertical integration to control supply chain costs and is exploring international expansion in Latin America and Europe, though U.S. growth remains the primary focus.
Key Risks and Contingencies:
- Internal Controls: The company disclosed a material weakness in internal control over financial reporting that has not been remediated as of December 31, 2024. This weakness relates to insufficient technical accounting personnel and IT general controls, which previously led to restatements of 2022 financial statements.
- Regulatory Scrutiny: The business relies on compounded bioidentical hormones regulated by the FDA. Changes in FDA policy regarding compounding or the implementation of National Academies of Sciences, Engineering, and Medicine (NASEM) recommendations could materially impact operations.
- Legal Proceedings: Pending litigation includes a name, image, and likeness (NIL) claim by Cindy Latch (temporary injunction granted) and a renewed NIL claim by Dr. Gary S. Donovitz (temporary injunction granted, currently under appeal).
- Liquidity: Cash reserves decreased significantly from $89.0 million to $39.3 million due to litigation settlements and acquisitions. The company has a $50.0 million revolving credit facility available.
Investor Verification Checklist
- Internal Control Remediation: Verify the timeline and specific steps management is taking to remediate the material weakness in internal controls over financial reporting.
- Litigation Exposure: Monitor the status of the Cindy Latch and Gary S. Donovitz NIL lawsuits, as temporary injunctions are currently in place restricting the use of their likenesses.
- Share Repurchase Liability: Review the cash flow impact of the $128.4 million share repurchase liability arising from litigation settlements, which is being paid over three years.
- Supply Chain Concentration: Assess the risk associated with the termination of the AnazaoHealth agreement (effective May 1, 2025) and the company's ability to meet demand through its newly acquired Asteria Health facility.
- Revenue Quality: Analyze the sustainability of revenue growth given the decline in dietary supplement sales and the tiered pricing structure that reduces fees as patient volume increases.